

Recommendations from York and Scarborough Medicines Commissioning Committee July 2014

Drug and Brand name	Indication	Recommendation	Place in therapy	RAG status	Potential full year cost impact Vale of York CCG
Eflornithine 11.5% cream (Vaniqa®)	Facial hirsutism in women	Approved	Supported for use in patients where there is an underlying clinical condition identified as the cause of hirsutism. Not commissioned for familial and idiopathic hirsutism.	Green	Represents a review of existing position. Spend April 13 to April 14 is £19,272.30.
Canagliflozin (Invokana®)	Oral therapy for type 2 diabetes	Approved – NICE Appraisal	Please see attached NICE Update	Green	Uptake likely less than NICE predict. Prescribing data shows for the period of May'13 to April'14 there have been only 46 prescribed items of dapagliflozin in Vale of York CCG (spend = £1656.21) which is treatment within the same drug class as canagliflozin.
Methotrexate 10mg tablets	All indications for oral therapy	Not approved	Recommended that only methotrexate 2.5mg tablets remain formulary choice on patient safety grounds.	As per amber shared care guidelines	
Duodopa® intestinal gel (Levodopa/carbidopa)	Parkinson's Disease	Change in commissioning responsibilities	NHS England now responsible for the commissioning arrangements for this specialist treatment	As per NHS England recommendation. Not suitable for GP prescribing.	Nil